Literature DB >> 12894502

Diverse responses between human pancreatic cancer cell lines to native alpha 1-antitrypsin and its C-terminal fragment.

Inga Zelvyte1, Bodil Ohlsson, Jan Axelson, Sabina Janciauskiene.   

Abstract

BACKGROUND: Previous studies imply that human pancreatic cancer cells have a wide heterogeneity and their exposure to various agents may give unpredictable results in clinical situations.
MATERIALS AND METHODS: The cell lines LPC-3, -5 and -10, established from primary cultures of pancreatic adenocarcinoma, were exposed to 5 microM of AAT or its C-terminal peptide C-36 for 24 hours and analysed for cytokines by an enzyme-linked immunosorbent assay and for NF kappa B by the electrophoretic mobility shift assay.
RESULTS: Native AAT lowers TGF-beta 1 levels and increases NF-kappa B activity in LPC-3 cells, while C-36 increases TGF-beta 1 levels and up-regulates NF-kappa B in LPC-5 cells. In LPC-10 cells AAT lowers TGF-beta 1. However, both AAT and C-36 fail to cause a change in NF-kappa B expression. For LPC-10 cells treated with C-36 IL-6 and TNF-alpha levels also increase.
CONCLUSION: Our findings provide evidence that human cancer cell lines originating from primary pancreatic tumors do not have a uniform response to the same stimulus which shows a great heterogenicity among pancreatic cancer cells. Serine proteinase inhibitor, AAT, dependent on its molecular form, is also found to exert diverse effects on the properties of tumour cells confirming the complexity of cell-protein interaction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12894502

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human colorectal carcinoma tissue.

Authors:  Liang-Liang Yu; Hong-Gang Yu; Jie-Ping Yu; He-Sheng Luo; Xi-Ming Xu; Jun-Hua Li
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

2.  Alpha-1-Antitrypsin Antagonizes Cisplatin-Induced Cytotoxicity in Prostate Cancer (PC3) and Melanoma Cancer (A375) Cell Lines.

Authors:  Mila Ljujic; Sanja Mijatovic; Mirna Z Bulatovic; Marija Mojic; Danijela Maksimovic-Ivanic; Dragica Radojkovic; Aleksandra Topic
Journal:  Pathol Oncol Res       Date:  2016-09-12       Impact factor: 3.201

3.  A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.

Authors:  G Deplanque; M Demarchi; M Hebbar; P Flynn; B Melichar; J Atkins; E Nowara; L Moyé; D Piquemal; D Ritter; P Dubreuil; C D Mansfield; Y Acin; A Moussy; O Hermine; P Hammel
Journal:  Ann Oncol       Date:  2015-04-09       Impact factor: 32.976

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.